Cargando…

Impact of Donepezil Supplementation on Alzheimer’s Disease-like Pathology and Gut Microbiome in APP/PS1 Mice

Based on published information, the occurrence and development of Alzheimer’s disease (AD) are potentially related to gut microbiota changes. Donepezil hydrochloride (DH), which enhances cholinergic activity by blocking acetylcholinesterase (AChE), is one of the first-line drugs for AD treatment app...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuan, Wu, Mengyao, Kong, Mengmeng, Sui, Shaomei, Wang, Qi, He, Yan, Gu, Jinsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537997/
https://www.ncbi.nlm.nih.gov/pubmed/37764150
http://dx.doi.org/10.3390/microorganisms11092306
_version_ 1785113225340125184
author Li, Yuan
Wu, Mengyao
Kong, Mengmeng
Sui, Shaomei
Wang, Qi
He, Yan
Gu, Jinsong
author_facet Li, Yuan
Wu, Mengyao
Kong, Mengmeng
Sui, Shaomei
Wang, Qi
He, Yan
Gu, Jinsong
author_sort Li, Yuan
collection PubMed
description Based on published information, the occurrence and development of Alzheimer’s disease (AD) are potentially related to gut microbiota changes. Donepezil hydrochloride (DH), which enhances cholinergic activity by blocking acetylcholinesterase (AChE), is one of the first-line drugs for AD treatment approved by the Food and Drug Administration (FDA) of the USA. However, the potential link between the effects of DH on the pathophysiological processes of AD and the gut microbiota remains unclear. In this study, pathological changes in the brain and colon, the activities of superoxide dismutase (SOD) and AChE, and changes in intestinal flora were observed. The results showed that Aβ deposition in the prefrontal cortex and hippocampus of AD mice was significantly decreased, while colonic inflammation was significantly alleviated by DH treatment. Concomitantly, SOD activity was significantly improved, while AChE was significantly reduced after DH administration. In addition, the gut microbiota community composition of AD mice was significantly altered after DH treatment. The relative abundance of Akkermansia in the AD group was 54.8% higher than that in the N group. The relative abundance of Akkermansia was increased by 18.3% and 53.8% in the AD_G group and the N_G group, respectively. Interestingly, Akkermansia showed a potential predictive value and might be a biomarker for AD. Molecular docking revealed the binding mode and major forces between DH and membrane proteins of Akkermansia. The overall results suggest a novel therapeutic mechanism for treating AD and highlight the critical role of gut microbiota in AD pathology.
format Online
Article
Text
id pubmed-10537997
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105379972023-09-29 Impact of Donepezil Supplementation on Alzheimer’s Disease-like Pathology and Gut Microbiome in APP/PS1 Mice Li, Yuan Wu, Mengyao Kong, Mengmeng Sui, Shaomei Wang, Qi He, Yan Gu, Jinsong Microorganisms Article Based on published information, the occurrence and development of Alzheimer’s disease (AD) are potentially related to gut microbiota changes. Donepezil hydrochloride (DH), which enhances cholinergic activity by blocking acetylcholinesterase (AChE), is one of the first-line drugs for AD treatment approved by the Food and Drug Administration (FDA) of the USA. However, the potential link between the effects of DH on the pathophysiological processes of AD and the gut microbiota remains unclear. In this study, pathological changes in the brain and colon, the activities of superoxide dismutase (SOD) and AChE, and changes in intestinal flora were observed. The results showed that Aβ deposition in the prefrontal cortex and hippocampus of AD mice was significantly decreased, while colonic inflammation was significantly alleviated by DH treatment. Concomitantly, SOD activity was significantly improved, while AChE was significantly reduced after DH administration. In addition, the gut microbiota community composition of AD mice was significantly altered after DH treatment. The relative abundance of Akkermansia in the AD group was 54.8% higher than that in the N group. The relative abundance of Akkermansia was increased by 18.3% and 53.8% in the AD_G group and the N_G group, respectively. Interestingly, Akkermansia showed a potential predictive value and might be a biomarker for AD. Molecular docking revealed the binding mode and major forces between DH and membrane proteins of Akkermansia. The overall results suggest a novel therapeutic mechanism for treating AD and highlight the critical role of gut microbiota in AD pathology. MDPI 2023-09-13 /pmc/articles/PMC10537997/ /pubmed/37764150 http://dx.doi.org/10.3390/microorganisms11092306 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Yuan
Wu, Mengyao
Kong, Mengmeng
Sui, Shaomei
Wang, Qi
He, Yan
Gu, Jinsong
Impact of Donepezil Supplementation on Alzheimer’s Disease-like Pathology and Gut Microbiome in APP/PS1 Mice
title Impact of Donepezil Supplementation on Alzheimer’s Disease-like Pathology and Gut Microbiome in APP/PS1 Mice
title_full Impact of Donepezil Supplementation on Alzheimer’s Disease-like Pathology and Gut Microbiome in APP/PS1 Mice
title_fullStr Impact of Donepezil Supplementation on Alzheimer’s Disease-like Pathology and Gut Microbiome in APP/PS1 Mice
title_full_unstemmed Impact of Donepezil Supplementation on Alzheimer’s Disease-like Pathology and Gut Microbiome in APP/PS1 Mice
title_short Impact of Donepezil Supplementation on Alzheimer’s Disease-like Pathology and Gut Microbiome in APP/PS1 Mice
title_sort impact of donepezil supplementation on alzheimer’s disease-like pathology and gut microbiome in app/ps1 mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537997/
https://www.ncbi.nlm.nih.gov/pubmed/37764150
http://dx.doi.org/10.3390/microorganisms11092306
work_keys_str_mv AT liyuan impactofdonepezilsupplementationonalzheimersdiseaselikepathologyandgutmicrobiomeinappps1mice
AT wumengyao impactofdonepezilsupplementationonalzheimersdiseaselikepathologyandgutmicrobiomeinappps1mice
AT kongmengmeng impactofdonepezilsupplementationonalzheimersdiseaselikepathologyandgutmicrobiomeinappps1mice
AT suishaomei impactofdonepezilsupplementationonalzheimersdiseaselikepathologyandgutmicrobiomeinappps1mice
AT wangqi impactofdonepezilsupplementationonalzheimersdiseaselikepathologyandgutmicrobiomeinappps1mice
AT heyan impactofdonepezilsupplementationonalzheimersdiseaselikepathologyandgutmicrobiomeinappps1mice
AT gujinsong impactofdonepezilsupplementationonalzheimersdiseaselikepathologyandgutmicrobiomeinappps1mice